Ignite Creation Date:
2024-05-06 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 2:50 PM
Study NCT ID:
NCT05698771
Status:
RECRUITING
Last Update Posted:
2023-01-27
First Post:
2023-01-16
Brief Title:
NAD-brain a Pharmacokinetic Study of NAD Replenishment Therapy
Sponsor:
Haukeland University Hospital
Organization:
Haukeland University Hospital
Study Overview
Official Title:
NAD-brain a Pharmacokinetic Study of NAD Replenishment Therapy
Status:
RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NAD-brain
Brief Summary:
The objective of the NAD-brain study is to determine the blood and brain pharmacokinetics of NAD replenishment therapy NRT using Nicotinamide Riboside NR or Nicotinamide Mononucleotide NMN
Detailed Description:
The NAD-brain study will perform a parallel assessment of NAD replenishment therapy NRT pharmacokinetics in the blood and brain of healthy human subjects A total of 6-10 healthy individuals 3-5 men and 3-5 women will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods each of which will start with 8 days of daily intake of Nicotinamide Riboside NR 600mg x 2 or Nicotinamide Mononucleotide NMN 600mg x 2 The two 20-day periods will be 14 days apart to allow for washout of the previous compound Blood will be analyzed for NAD-metabolites The simultaneous change in NAD-metabolism over time in blood and brain will be assessed and blood and brain pharmacokinetics for NRT in humans will be established
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None